Implications The growing popularity of GLP-1 medications continues to potentially point to broader health benefits for American adults as obesity levels curtail and the diabetes rate levels off after years of increases
In SELECT, investigators were allowed to slow, decrease or pause treatment
AMPK and SIRT1: a long-standing partnership
Food and Drug Administration (FDA) on drugs related to endocrinology and metabolism
Changes in insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia [see Warnings and Precautions (5.6)] or hyperglycemia
Slowing the Gastric Rhythm: By slowing down food movement through the stomach, GLP-1 extends the time it takes for the body to process nutrients